Table 3 |
||||
|
Results of Cox regression analysis of survival predictors in 126 patients with BM. |
||||
| Variable |
Univariate analysis |
Multivariate analysis |
||
|
|
||||
| HR (95% CI) |
p Value |
HR (95% CI) |
p Value |
|
|
|
||||
| ER- and PR- vs ER or PR+ |
1.477 (1.006–2.168) |
0.047 |
1.656 (1.107–2.478) |
0.014* |
| HER2- vs HER2+ |
1.625 (1.125–2.347) |
0.010 |
1.608 (1.099–2.352) |
0.014* |
| Triple negative vs others |
1.758 (1.194–2.588) |
0.004 |
1.692 (1.137–2.518) |
0.010* |
| Age ≥ 45 yrs vs < 45 yrs |
1.815 (1.245–2.647) |
0.002 |
1.700 (1.155–2.504) |
0.007† |
| Disease free interval: < 24 months vs ≥ 24 months |
1.857 (1.258–2.740) |
0.002 |
1.379 (0.897–2.119) |
0.143† |
| Interval from recurrence to BM: < 12 months vs ≥ 12 months |
0.688 (0.478–0.988) |
0.043 |
0.702 (0.478–1.031) |
0.071† |
| Number of metastatic sites: ≥ 3 vs < 3 |
1.710 (1.155–2.532) |
0.007 |
1.769 (1.141–2.743) |
0.011† |
| Leptomeningeal disease: presence vs absence |
2.069 (1.153–3.713) |
0.015 |
2.865 (1.506–5.450) |
0.001† |
|
|
||||
|
Abbreviations: BM, brain metastasis; CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; HR, hazard ratio; PR, progesterone receptor. *Variables regarding triple receptor status were separately analyzed adjusting for other variables (age, disease free interval, interval from recurrence to BM, number of metastatic sites, leptomeningeal disease). †Each variable other than triple receptor status was adjusted with triple-negative vs others. |
||||
|
Nam et al. Breast Cancer Research 2008 10:R20 doi:10.1186/bcr1870 |
||||
